Selecta Biosciences
Pioneering RNA cell therapy for autoimmune disease.
Launch date
Employees
Market cap
CAD488m
Enterprise valuation
CAD197m (Public information from Sep 2024)
Share price
$16.54 SELB
Watertown Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 16.6m | 85.1m | 111m | 26.0m | 44.5m | 13.4m | 17.7m |
| % growth | 149 % | 413 % | 30 % | (77 %) | 71 % | (70 %) | 32 % |
| EBITDA | (56.7m) | (4.6m) | 16.2m | - | - | - | - |
| % EBITDA margin | (342 %) | (5 %) | 15 % | - | - | - | - |
| Profit | (68.9m) | (25.7m) | 35.4m | (220m) | (75.8m) | (79.3m) | (101m) |
| % profit margin | (415 %) | (30 %) | 32 % | (845 %) | (171 %) | (592 %) | (570 %) |
| EV / revenue | 19.7x | 4.5x | 1.6x | 4.1x | 1.9x | -0.6x | 7.3x |
| EV / EBITDA | -5.8x | -82.9x | 10.7x | - | - | - | - |
| R&D budget | 54.5m | 68.7m | 72.4m | - | - | - | - |
| R&D % of revenue | 328 % | 81 % | 65 % | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$2.5m | Seed | ||
$15.1m | Series B | ||
$15.0m | Series C | ||
$47.3m | Series D | ||
$22.0m | Series D | ||
| N/A | $5.3m | Early VC | |
| N/A | $4.5m | Debt | |
| N/A | $3.2m | Grant | |
| N/A | $5.9m | Early VC | |
$38.0m | Series E | ||
| N/A | N/A | IPO | |
| N/A | $5.0m | Post IPO Equity | |
$21.0m | Debt | ||
| N/A | $5.8m | Post IPO Equity | |
| N/A | $35.0m | Post IPO Debt | |
* | N/A | $38.7m | Post IPO Equity |
* | N/A | $60.3m | Private Placement VC |
* | N/A | Acquisition | |
| Total Funding | CAD293m | ||
Related Content
Recent News about Selecta Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
